AKAM vs GYRE · P/E 27, rev $2.17B vs rev $53.5M
Akamai Technologies Inc (AKAM) versus Gyre Therapeutics Inc. (GYRE) — a side-by-side from cached financials, not a winner call.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Latest reported GYRE revenue for 2026-06-30 was $53.5M. Net income was -$32.8M. GYRE currently screens at market cap $589.9M.
AKAM currently screens at market cap $11.31B and trailing P/E 26.7. GYRE currently screens at market cap $589.9M.
Not investment advice. Open the AKAM and GYRE stock pages for the full models.
Not investment advice.